We are live on ! Find out more
SRNE

Sorrento Therapeutics, Inc.

Delisted

SRNE was delisted on the 22nd of February, 2023.

68 hedge funds and large institutions have $69.3M invested in Sorrento Therapeutics, Inc. in 2016 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

145% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 11

19% less funds holding

Funds holding: 8468 (-16)

39% less capital invested

Capital invested by funds: $114M → $69.3M (-$44.9M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

64% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 25

76% less call options, than puts

Call options by funds: $30K | Put options by funds: $123K

Holders
68
Holders Change
-16
Holders Change %
-19.05%
% of All Funds
1.81%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
9
Increased
27
Reduced
11
Closed
25
Calls
$30K
Puts
$123K
Net Calls
-$93K
Net Calls Change
-$542K

SRNE Hedge Fund Activity: Q1 2016 in Review

68 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q1 2016, worth a combined $69.3M — down 39% from $114M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of SRNE and 9 opened new positions — a net loss of 16 holders — while 11 trimmed existing stakes and 27 added.

The largest buyer was TFS Capital, adding an estimated $1.04M. The largest seller was Millennium Management, cutting an estimated $1.77M.

  • 68 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q1 2016, down from 84 in Q4 2015.
  • Funds reported $69.3M of Sorrento Therapeutics, Inc. stock for Q1 2016, down 39% quarter-over-quarter.
  • 9 funds opened new Sorrento Therapeutics, Inc. positions in Q1 2016 and 25 closed out, a net change of -16 holders.
  • The largest Sorrento Therapeutics, Inc. buyer in Q1 2016 was TFS Capital, an estimated $1.04M added.
  • The largest Sorrento Therapeutics, Inc. seller in Q1 2016 was Millennium Management, an estimated $1.77M sold.

Based on aggregated 13F filings for Q1 2016.